New tuberculosis drugs on the horizon

Tuberculosis (TB) remains a major global health concern whose control has been exacerbated by HIV and the emergence of multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) strains of Mycobacterium tuberculosis. The demand for new and faster acting TB drugs is thus greater than ever. In the past decade intensive efforts have been made to discover new leads for TB drug development using both target-based and cell-based approaches. Here, we describe the most promising anti-tubercular drug candidates that are in clinical development and introduce some nitro-aromatic compounds that inhibit a new target, DprE1, an essential enzyme involved in a crucial step in mycobacterial cell wall biosynthesis.


Published in:
Current opinion in microbiology, 14, 5, 570-6
Year:
2011
ISSN:
1879-0364
Keywords:
Laboratories:




 Record created 2011-11-24, last modified 2018-03-17


Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)